One protein near the start of this pathway is activated when its N-terminal domain is cleaved to make a SFLLRN sequence terminal. That sequence then acts as a tethered ligand, initiating trans-membrane signalling, and is found in PAR1. This process can also be initiated by the activation of kallikrein, which itself leads to the cleavage of high-molecular-weight kininogen. One step in this process is mediated by a glycoprotein stored in ?-granules and involves the adhesion of specialized cell fragments to (*) collagen, and a family of drugs targeting this pathway are ba
One protein near the start of this pathway is activated when its N-terminal domain is cleaved to make a SFLLRN sequence terminal. That sequence then acts as a tethered ligand, initiating trans-membrane signalling, and is found in PAR1. This process can also be initiated by the activation of kallikrein, which itself leads to the cleavage of high-molecular-weight kininogen. One step in this process is mediated by a glycoprotein stored in ?-granules and involves the adhesion of specialized cell fragments to (*) collagen, and a family of drugs targeting this pathway are based on coumarin. One type of cells involved in this process release calcium ions and thromboxane A2 which helps recruit more cells that participate in this process.  For 10 points, name this process which results in the conversion of fibrinogen to fibrin and subsequent network formation of an impermeable structure which notably includes platelets.
One protein near the start of this pathway is activated when its N-terminal domain is cleaved to make a SFLLRN sequence terminal.
{Blood clotting} or {coagulation}